the DBL report

Issue #109, July 2019

An Official Accompaniment to the Alberta Drug Benefit List (ADBL) produced by Alberta Blue Cross

The Expert Committee on Drug Evaluation and Therapeutics (ECDET)

In this issue:

Brief Summary of Drug Review Activities

The Expert Committee on Drug Evaluation and Therapeutics met on May 13, 2019. The Committee reviewed Manufacturer submissions for twelve (12) Drug Products for potential listing, or change in listing, on the *ADBL*. The Committee also considered information for a number of supplementary assessments of the coverage status of four (4) Drug Products.

In addition to Drug Products reviewed by the Expert Committee, three (3) Drug Products underwent Expedited Review for listing on the *ADBL* effective July 1, 2019.

The following are highlights of recent changes to the *ADBL* and other topics of general interest. A complete list of changes, as well as the full *ADBL* may be accessed at https://www.ab.bluecross.ca/dbl/publications.html

Highlights of Products Originally Reviewed via the Common Drug Review (CDR)

The following Drug Product was reviewed by CDR and the Expert Committee and added to the *ADBL* effective July 1, 2019:

- **PROBUPHINE* 80 mg subdermal implant** (buprenorphine hydrochloride) (KTI) via Special Authorization (SA)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.
Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (07/2019)

Highlights of Interchangeable (IC) Drug Products Added

Addition of the following Entry IC Drug Product to the *ADBL* has resulted in the creation of a New IC Grouping, effective July 1, 2019:

- **MAR-FEBUXOSTAT* 80 mg tablet** (febuxostat) (MAR) via Special Authorization

Highlights of Line Extension Drug Products Reviewed for the ADBL

Addition of the following Drug Products to the *ADBL* effective July 1, 2019:

- **AA-CLOZAPINE 50 mg & 200 mg tablets** (clozapine) (AAP)

Special Authorization Criteria Changes

The Special Authorization criteria for coverage for the following Drug Product has been revised effective June 17, 2019:

- **SPINRAZA* 2.4 mg/mL injection** (nusinersen sodium) (BIO)

A complete list of changes, as well as the full ADBL may be accessed at https://www.ab.bluecross.ca/dbl/publications.html.

Please refer to the current ADBL for explanations of coverage, including a listing of coverage criteria (where applicable).*

ABC 81171 (06/2019)